¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
Æú¸® Ä«Å×ÅÍ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è Æú¸® Ä«Å×ÅÍ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 25¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025³âºÎÅÍ 2030³â±îÁö 5.86%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿ä½Ç±Ý, ½Å°æÀμº ¹æ±¤ µî ºñ´¢±â°ú ÁúȯÀÇ À¯º´·ü Áõ°¡, ô¼ö ¼Õ»ó ¹ß»ý·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, À¯¸®ÇÑ »óȯ Á¤Ã¥ µîÀ¸·Î ÀÎÇØ Æú¸® Ä«Å×ÅÍ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Äڷγª19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ Àü ¼¼°è ȯÀÚ Áý´ÜÀº Å« ÀÇ·á ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÇ·á ¼ºñ½º¿¡ ´ëÇÑ Á¢±ÙÀÌ Á¦Çѵʿ¡ µû¶ó ´Ù¾çÇÑ Áúº´À» ¾Î°í Àִ ȯÀÚµéÀº ¿¾ÇÇÑ ÀÇ·á ¼ºñ½º¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. Àü¿°º´Àº Æú¸® Ä«Å×ÅÍ ÆÇ¸Å¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Áúº´ÀÇ È®»êÀ» ¸·±â À§ÇØ ¼ö¼úÀÌ ÀÚÁÖ ¿¬±âµÇ°í ½ÉÁö¾î ÁߴܵDZ⵵ ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 8¿ù¿¡ ¹ßÇ¥µÈ ºñ´¢±â°ú ·¹Áö´øÆ® Á¶»ç¿¡ µû¸£¸é ÀÌÅ»¸®¾Æ¿¡¼´Â °³º¹ ¼ö¼ú, ÃÖ¼Ò Ä§½À ¼ö¼ú, ³»½Ã°æ ¼ö¼ú, Áø·á¼Ò ¹æ¹® ¹× Áø´Ü ÀýÂ÷°¡ ¸ðµÎ 40-100% °¨¼ÒÇß½À´Ï´Ù.
¶ÇÇÑ ÀεµÀÇ ·¹Áö´øÆ®µéÀº ¼ö¼ú °Ç¼ö°¡ 90% °¨¼ÒÇß´Ù°í º¸°íÇßÀ¸¸ç, 80% ÀÌ»óÀÇ ·¹Áö´øÆ®µéÀÌ ±³À°¿¡ ¿µÇâÀ» ¹Þ¾Ò´Ù°í »ý°¢ÇÑ´Ù°í ´äÇß½À´Ï´Ù. °°Àº ¼Ò½ÄÅë¿¡ µû¸£¸é, ¶óƾ¾Æ¸Þ¸®Ä«¿Í ½ºÆäÀÎÀÇ ºñ´¢±â°ú ·¹Áö´øÆ®µéÀ» ´ë»óÀ¸·Î ÇÑ Á¶»ç¿¡¼ 15%°¡ ºñ´¢±â°ú Áø·á½ÇÀ» Æó¼âÇÏ°í ¸ðµç Ȱµ¿À» Äڷγª19 ȯÀÚ Áø·á¿¡ ÁýÁßÇϰí ÀÖ´Ù°í ´äÇß½À´Ï´Ù. ±× °á°ú, 2020³â Äڷγª19 ÆÒµ¥¹ÍÀÌ ´ÚÄ¡¸é¼ Æú¸® Ä«Å×ÅÍÀÇ ¸ÅÃâÀº ±Þ°¨Çß½À´Ï´Ù.
¼¼°è ´ëºÎºÐÀÇ ±¹°¡¿¡¼ Àá±Ý ±ÔÁ¦°¡ ¿Ïȵǰí ÀϺΠ¼±ÅÃÀû ¼ö¼úÀÌ Àç°³µÇ±â ½ÃÀÛÇÔ¿¡ µû¶ó ½ÃÀåÀº ȸº¹µÇ°í ¿¹Ãø ±â°£ µ¿¾È È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ºñ´¢±â°ú ÁúȯÀÇ ³ôÀº ºóµµ, ±â¼ú °³¼±, ´Ù¾çÇÑ ±â¾÷ÀÇ Àü·«Àû Çൿ, ³ëÀÎ Àα¸ Áõ°¡´Â Æú¸® Ä«Å×ÅÍ »ê¾÷ È®ÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, 2022³â 6¿ù, Sanford Health´Â InnoCare Urologics LLC¿¡ ±â¼ú ¶óÀ̼±½º¸¦ ºÎ¿©Çß½À´Ï´Ù. ½ºÅÄÆ÷µå ´ëÇÐÀÇ °³¾÷Àǰ¡ ¿ì¹ßÀû ÀÎ ÀÎÃâ ¼Õ»óÀ¸·Î ÀÎÇÑ ¼Õ»óÀ» ÁÙÀ̱â À§ÇØ ¿äµµ Ä«Å×Å͸¦ ¹ß¸íÇßÀ¸¸ç, InnoCare´Â ÇÊ¿äÇÑ Å×½ºÆ®¸¦ ¸¶Ä¡°í Á¦Á¶¾÷ü¿Í µðÀÚÀÎÀ» È®Á¤Çß½À´Ï´Ù. ´ÙÀ½ ´Ü°è´Â ¹Ì±¹ FDA¿¡ Á¦ÃâÇÏ¿© ½ÃÆÇ Çã°¡¸¦ ¹Þ´Â °ÍÀÔ´Ï´Ù.
Æú¸® Ä«Å×ÅÍ ½ÃÀå ÇÏÀ̶óÀÌÆ®
- Á¦Ç° À¯Çüº°·Î´Â 2024³â ¾ç¹æÇâ Æú¸® Ä«Å×ÅͰ¡ 51.38%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ¿ä·Î°¨¿°Áõ(UTI), ½ÅÀå°á¼®, ¿ä°ü°á¼®°ú °°Àº ºñ´¢±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡¿Í ´õºÒ¾î ÃÖ¼Òħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÎ¹®ÀÌ 2024³â ¾à 52.83%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ÁÖ·Î ¿Ü°ú ¼ö¼ú Áõ°¡¿Í ´Ù¾çÇÑ ¸¸¼º ÁúȯÀ» ¾Î°í Àִ ȯÀÚ ¼ö Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.
- ºÏ¹Ì Æú¸® Ä«Å×ÅÍ ½ÃÀåÀº 2024³â 31.62% ÀÌ»óÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ºÐ¼® ¹æ¹ý, ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Æú¸® Ä«Å×ÅÍ ½ÃÀå : º¯µ¿ ¿äÀÎ, µ¿Çâ, ¹üÀ§
- ½ÃÀå ¿¬°ü Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ½ÃÀå ±âȸ ºÐ¼®
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦ ºÐ¼®
- Æú¸® Ä«Å×ÅÍ ½ÃÀå : ºÐ¼® Åø
- ¾÷°è ºÐ¼® : PorterÀÇ Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå Æú¸® Ä«Å×ÅÍ ½ÃÀå : Á¦Ç°º° ÃßÁ¤, µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀå º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀå : ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç°º°(2018-2030³â)
- 2-way Æú¸® Ä«Å×ÅÍ
- 3-way Æú¸® Ä«Å×ÅÍ
- 4-way Æú¸® Ä«Å×ÅÍ
Á¦5Àå Æú¸® Ä«Å×ÅÍ ½ÃÀå : ÀûÀÀÁõº° ÃßÁ¤, µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀå º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀå : ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÀûÀÀÁõº°(2018-2030³â)
- ¿ä½Ç±Ý
- Àü¸³¼± ºñ´ëÁõ
- ôÃß ¼Õ»ó
- ±âŸ
Á¦6Àå Æú¸® Ä«Å×ÅÍ µð¹ÙÀ̽º ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤, µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀå º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀå : ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
- º´¿ø
- º´¿ø : ½ÃÀå Ãß»ê, ¿¹Ãø(2018-2030³â)
- Àå±â¿ä¾ç½Ã¼³
- Àå±â¿ä¾ç½Ã¼³ : ½ÃÀå Ãß»ê, ¿¹Ãø(2018-2030³â)
- ±âŸ
- ±âŸ : ½ÃÀå Ãß»ê, ¿¹Ãø(2018-2030³â)
Á¦7Àå Æú¸® Ä«Å×ÅÍ ½ÃÀå : Àç·áº° ÃßÁ¤, µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀå º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀå : ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Àç·áº°(2018-2030³â)
- ½Ç¸®ÄÜ Æú¸® Ä«Å×ÅÍ
- ¶óÅØ½ºÆ÷¸®Ä«Å×ÀÌÅÚ
Á¦8Àå Æú¸® Ä«Å×ÅÍ ½ÃÀå : Áö¿ªº° ÃßÁ¤, µ¿Ç⠺м®
- Áö¿ª ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м®(2018-2030³â)
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Àεµ
- Áß±¹
- Çѱ¹
- È£ÁÖ
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦9Àå °æÀï ±¸µµ
- ½ÃÀå ÁøÃâ±â¾÷ ºÐ·ù
- ÁÖ¿ä ±â¾÷ °³¿ä
- Sterimed Group.
- ANGIPLAST PRIVATE LIMITED
- HEMC(Hospital Equipment Manufacturing Company)
- Cardinal Health
- Advin Health Care
- AdvaCare Pharma
- Teleflex Incorporated
- Bactiguard AB
- Medtronic
- B. Braun SE
- Ribbel International Limited
- Coloplast Corp
- È÷Æ®¸Ê ºÐ¼®/±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®
- ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ÃßÁ¤ ºÐ¼®(2024³â)
- ±âŸ ÁÖ¿ä ±â¾÷ ¸®½ºÆ®
LSH 25.04.02
Foley Catheter Market Growth & Trends:
The global foley catheter market size is expected to reach USD 2.58 billion by 2030, expected to expand at a CAGR of 5.86% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for foley catheters is anticipated to increase owing to the rising prevalence of urological diseases such as urinary incontinence, neurogenic bladder, growing incidence of spinal cord injuries, increasing elderly population, and favorable reimbursement policies.
The worldwide patient population faces a substantial healthcare challenge as a result of the COVID-19 pandemic. Patients suffering from different diseases have received subpar care as a result of limited access to medical services. The pandemic negatively affected sales of foley catheters. To stop the illness from spreading, surgeries are frequently delayed or even canceled. For instance, open and minimally invasive operations, endoscopic surgeries, clinic visits, and diagnostic procedures all fell by 40-100% in Italy, according to urology residents' research published in August 2021.
Additionally, residents in India reported a 90% drop in surgical volume, and more than 80% of them believed their education had been affected. According to the same source, a survey of urology residents in Latin America and Spain found that 15% had their urological service closed, with all activity devoted to COVID-19 patients. As a result, with the advent of the COVID-19 pandemic in 2020, foley catheter sales plummeted.
The majority of nations across the world have started to loosen lockup regulations and restart some elective surgeries, thus the market is anticipated to bounce back and expand over the projected period. Additionally, a high frequency of urologic disorders, technological improvements, strategic actions made by various players, and an increase in the elderly population are the primary drivers of the foley catheters industry expansion.
For instance, in June 2022, Sanford Health licensed its technology to InnoCare Urologics LLC. A Stanford health practitioner invented a urinary catheter for reducing damage from accidental pullout injuries. InnoCare has finished the necessary testing and has finalized the design with a manufacturer. Its next step is submission to the U.S. FDA to obtain market clearance.
Foley Catheter Market Highlights
- By product type, 2-way foley catheters accounted for the largest market share of 51.38% in 2024. The growth of the segment is due to the increasing prevalence of urological disorders such as urinary tract infections (UTIs), kidney and ureteral stones, rising preference for minimally invasive surgeries coupled with the rising geriatric population.
- Based on the end user, the hospital segment captured the largest market share with around 52.83% in 2024. The growth of this segment can mainly be attributed to a consequent rise in surgical procedures and an increase in the number of patients suffering from various chronic ailments.
- North America foley catheter market held the largest revenue share, more than 31.62%, in 2024.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Foley Catheters Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rise in geriatric population
- 3.2.1.2. Growing prevalence of urological disorders
- 3.2.1.3. Rising demand for antimicrobial catheters
- 3.2.2. Market restraint analysis
- 3.2.2.1. Growing concerns regarding Catheter-Associated Urinary Tract Infection (CAUTI)
- 3.2.3. Market opportunity analysis
- 3.2.3.1. Increasing focus on research & development
- 3.2.3.2. Growth potential in emerging economies in foley catheters market
- 3.2.4. Market challenge analysis
- 3.2.4.1. Growing number of product recalls
- 3.3. Foley Catheters Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political & Legal Landscape
- 3.3.2.2. Economic and Social Landscape
- 3.3.2.3. Technological landscape
Chapter 4. Foley Catheters Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Foley Catheters Market Movement Analysis
- 4.3. Global Foley Catheters Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. 2-way Foley Catheters
- 4.4.1. 2-way foley catheters market estimates and forecast 2018 to 2030 (USD Million)
- 4.5. 3-way Foley Catheters
- 4.5.1. 3-way foley catheters market estimates and forecast 2018 to 2030 (USD Million)
- 4.6. 4-way Foley Catheters
- 4.6.1. 4-way foley catheters market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Foley Catheters Market: Indication Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Foley Catheters Market Movement Analysis
- 5.3. Global Foley Catheters Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
- 5.4. Urinary Incontinence
- 5.4.1. Urinary incontinence market estimates and forecast 2018 to 2030 (USD Million)
- 5.5. Enlarged Prostate Gland/BPH
- 5.5.1. Enlarged prostate gland/BPH market estimates and forecast 2018 to 2030 (USD Million)
- 5.6. Spinal Cord Injury
- 5.6.1. Spinal cord injury market estimates and forecast 2018 to 2030 (USD Million)
- 5.7. Others
- 5.7.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Foley Catheters Devices: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Foley Catheters Market Movement Analysis
- 6.3. Global Foley Catheters Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 6.4. Hospitals
- 6.4.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
- 6.5. Long Term Care Facilities
- 6.5.1. Long term care facilities market estimates and forecast 2018 to 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Foley Catheters Market: Material Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Foley Catheters Market Movement Analysis
- 7.3. Global Foley Catheters Market Size & Trend Analysis, by Material, 2018 to 2030 (USD Million)
- 7.4. Silicone Foley Catheters
- 7.4.1. Silicone foley catheters market estimates and forecast 2018 to 2030 (USD Million)
- 7.5. Latex Foley Catheters
- 7.5.1. Latex foley catheters market estimates and forecast 2018 to 2030 (USD Million)
Chapter 8. Foley Catheters Market: Regional Estimates & Trend Analysis
- 8.1. Regional Dashboard
- 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
- 8.3. North America
- 8.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
- 8.3.2. U.S.
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Competitive scenario
- 8.3.2.3. Regulatory framework
- 8.3.2.4. Reimbursement scenario
- 8.3.2.5. U.S. market estimates and forecasts, 2018 - 2030
- 8.3.3. Canada
- 8.3.3.1. Key country dynamics
- 8.3.3.2. Competitive scenario
- 8.3.3.3. Regulatory framework
- 8.3.3.4. Reimbursement scenario
- 8.3.3.5. Canada market estimates and forecasts, 2018 - 2030
- 8.3.4. Mexico
- 8.3.4.1. Key country dynamics
- 8.3.4.2. Competitive scenario
- 8.3.4.3. Regulatory framework
- 8.3.4.4. Reimbursement scenario
- 8.3.4.5. Mexico market estimates and forecasts, 2018 - 2030
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Key country dynamics
- 8.4.1.2. Competitive scenario
- 8.4.1.3. Regulatory framework
- 8.4.1.4. Reimbursement scenario
- 8.4.1.5. UK market estimates and forecasts, 2018 - 2030
- 8.4.2. Germany
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Competitive scenario
- 8.4.2.3. Regulatory framework
- 8.4.2.4. Reimbursement scenario
- 8.4.2.5. Germany market estimates and forecasts, 2018 - 2030
- 8.4.3. France
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Competitive scenario
- 8.4.3.3. Regulatory framework
- 8.4.3.4. Reimbursement scenario
- 8.4.3.5. France market estimates and forecasts, 2018 - 2030
- 8.4.4. Italy
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Competitive scenario
- 8.4.4.3. Regulatory framework
- 8.4.4.4. Reimbursement scenario
- 8.4.4.5. Italy market estimates and forecasts, 2018 - 2030
- 8.4.5. Spain
- 8.4.5.1. Key country dynamics
- 8.4.5.2. Competitive scenario
- 8.4.5.3. Regulatory framework
- 8.4.5.4. Reimbursement scenario
- 8.4.5.5. Spain market estimates and forecasts, 2018 - 2030
- 8.4.6. Denmark
- 8.4.6.1. Key country dynamics
- 8.4.6.2. Competitive scenario
- 8.4.6.3. Regulatory framework
- 8.4.6.4. Reimbursement scenario
- 8.4.6.5. Denmark market estimates and forecasts, 2018 - 2030
- 8.4.7. Sweden
- 8.4.7.1. Key country dynamics
- 8.4.7.2. Competitive scenario
- 8.4.7.3. Regulatory framework
- 8.4.7.4. Reimbursement scenario
- 8.4.7.5. Sweden market estimates and forecasts, 2018 - 2030
- 8.4.8. Norway
- 8.4.8.1. Key country dynamics
- 8.4.8.2. Competitive scenario
- 8.4.8.3. Regulatory framework
- 8.4.8.4. Reimbursement scenario
- 8.4.8.5. Norway market estimates and forecasts, 2018 - 2030
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Competitive scenario
- 8.5.1.3. Regulatory framework
- 8.5.1.4. Reimbursement scenario
- 8.5.1.5. Japan market estimates and forecasts, 2018 - 2030
- 8.5.2. India
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Competitive scenario
- 8.5.2.3. Regulatory framework
- 8.5.2.4. Reimbursement scenario
- 8.5.2.5. India market estimates and forecasts, 2018 - 2030
- 8.5.3. China
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Competitive scenario
- 8.5.3.3. Regulatory framework
- 8.5.3.4. Reimbursement scenario
- 8.5.3.5. China market estimates and forecasts, 2018 - 2030
- 8.5.4. South Korea
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Competitive scenario
- 8.5.4.3. Regulatory framework
- 8.5.4.4. Reimbursement scenario
- 8.5.4.5. South Korea market estimates and forecasts, 2018 - 2030
- 8.5.5. Australia
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Competitive scenario
- 8.5.5.3. Regulatory framework
- 8.5.5.4. Reimbursement scenario
- 8.5.5.5. Australia market estimates and forecasts, 2018 - 2030
- 8.5.6. Thailand
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Competitive scenario
- 8.5.6.3. Regulatory framework
- 8.5.6.4. Reimbursement scenario
- 8.5.6.5. Thailand market estimates and forecasts, 2018 - 2030
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Competitive scenario
- 8.6.1.3. Regulatory framework
- 8.6.1.4. Reimbursement scenario
- 8.6.1.5. Brazil market estimates and forecasts, 2018 - 2030
- 8.6.2. Argentina
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Competitive scenario
- 8.6.2.3. Regulatory framework
- 8.6.2.4. Reimbursement scenario
- 8.6.2.5. Argentina market estimates and forecasts, 2018 - 2030
- 8.7. MEA
- 8.7.1. South Africa
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Competitive scenario
- 8.7.1.3. Regulatory framework
- 8.7.1.4. Reimbursement scenario
- 8.7.1.5. South Africa market estimates and forecasts, 2018 - 2030
- 8.7.2. Saudi Arabia
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Competitive scenario
- 8.7.2.3. Regulatory framework
- 8.7.2.4. Reimbursement scenario
- 8.7.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
- 8.7.3. UAE
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Competitive scenario
- 8.7.3.3. Regulatory framework
- 8.7.3.4. Reimbursement scenario
- 8.7.3.5. UAE market estimates and forecasts, 2018 - 2030
- 8.7.4. Kuwait
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Competitive scenario
- 8.7.4.3. Regulatory framework
- 8.7.4.4. Reimbursement scenario
- 8.7.4.5. Kuwait market estimates and forecasts, 2018 - 2030
Chapter 9. Competitive Landscape
- 9.1. Market Participant Categorization
- 9.2. Key Company Profiles
- 9.2.1. Sterimed Group.
- 9.2.1.1. Company overview
- 9.2.1.2. Financial performance
- 9.2.1.3. Product benchmarking
- 9.2.1.4. Strategic initiatives
- 9.2.2. ANGIPLAST PRIVATE LIMITED
- 9.2.2.1. Company overview
- 9.2.2.2. Financial performance
- 9.2.2.3. Product benchmarking
- 9.2.2.4. Strategic initiatives
- 9.2.3. HEMC (Hospital Equipment Manufacturing Company)
- 9.2.3.1. Company overview
- 9.2.3.2. Financial performance
- 9.2.3.3. Product benchmarking
- 9.2.3.4. Strategic initiatives
- 9.2.4. Cardinal Health
- 9.2.4.1. Company overview
- 9.2.4.2. Financial performance
- 9.2.4.3. Product benchmarking
- 9.2.4.4. Strategic initiatives
- 9.2.5. Advin Health Care
- 9.2.5.1. Company overview
- 9.2.5.2. Financial performance
- 9.2.5.3. Product benchmarking
- 9.2.5.4. Strategic initiatives
- 9.2.6. AdvaCare Pharma
- 9.2.6.1. Company overview
- 9.2.6.2. Financial performance
- 9.2.6.3. Product benchmarking
- 9.2.6.4. Strategic initiatives
- 9.2.7. Teleflex Incorporated
- 9.2.7.1. Company overview
- 9.2.7.2. Financial performance
- 9.2.7.3. Product benchmarking
- 9.2.7.4. Strategic initiatives
- 9.2.8. Bactiguard AB
- 9.2.8.1. Company overview
- 9.2.8.2. Financial performance
- 9.2.8.3. Product benchmarking
- 9.2.8.4. Strategic initiatives
- 9.2.9. Medtronic
- 9.2.9.1. Company overview
- 9.2.9.2. Financial performance
- 9.2.9.3. Product benchmarking
- 9.2.9.4. Strategic initiatives
- 9.2.10. B. Braun SE
- 9.2.10.1. Company overview
- 9.2.10.2. Financial performance
- 9.2.10.3. Product benchmarking
- 9.2.10.4. Strategic initiatives
- 9.2.11. Ribbel International Limited
- 9.2.11.1. Company overview
- 9.2.11.2. Financial performance
- 9.2.11.3. Product benchmarking
- 9.2.11.4. Strategic initiatives
- 9.2.12. Coloplast Corp
- 9.2.12.1. Company overview
- 9.2.12.2. Financial performance
- 9.2.12.3. Product benchmarking
- 9.2.12.4. Strategic initiatives
- 9.3. Heat Map Analysis/ Company Market Position Analysis
- 9.4. Estimated Company Market Share Analysis, 2024
- 9.5. List of Other Key Market Players